In last trading session, Acumen Pharmaceuticals Inc (NASDAQ:ABOS) saw 0.32 million shares changing hands with its beta currently measuring 0.14. Company’s recent per share price level of $2.22 trading at -$0.05 or -2.20% at ring of the bell on the day assigns it a market valuation of $133.38M. That closing price of ABOS’s stock is at a discount of -169.37% from its 52-week high price of $5.98 and is indicating a premium of 18.47% from its 52-week low price of $1.81. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.18 million shares which gives us an average trading volume of 421.43K if we extend that period to 3-months.

For Acumen Pharmaceuticals Inc (ABOS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.36 in the current quarter.

Acumen Pharmaceuticals Inc (NASDAQ:ABOS) trade information

Upright in the red during last session for losing -2.20%, in the last five days ABOS remained trading in the red while hitting it’s week-highest on Friday, 08/30/24 when the stock touched $2.22 price level, adding 22.11% to its value on the day. Acumen Pharmaceuticals Inc’s shares saw a change of -42.19% in year-to-date performance and have moved -21.00% in past 5-day. Acumen Pharmaceuticals Inc (NASDAQ:ABOS) showed a performance of -16.54% in past 30-days. Number of shares sold short was 1.85 million shares which calculate 5.32 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 68.29% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -215.32% in reaching the projected high whereas dropping to the targeted low would mean a loss of -215.32% for stock’s current value.

Acumen Pharmaceuticals Inc (ABOS) estimates and forecasts

Statistics highlight that Acumen Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -49.20% of value to its shares in past 6 months, showing an annual growth rate of -22.22% while that of industry is 17.90. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -54.03% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -20.32% while estimates for its earnings growth in next 5 years are of 1.60%.

Acumen Pharmaceuticals Inc (NASDAQ:ABOS)’s Major holders

Insiders are in possession of 11.24% of company’s total shares while institution are holding 78.45 percent of that, with stock having share float percentage of 88.38%. Investors also watch the number of corporate investors in a company very closely, which is 78.45% institutions for Acumen Pharmaceuticals Inc that are currently holding shares of the company. RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at ABOS for having 14.93 million shares of worth $36.14 million. And as of 2024-06-30, it was holding 24.965 of the company’s outstanding shares.

The second largest institutional holder is SANDS CAPITAL VENTURES, LLC, which was holding about 3.42 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.713 of outstanding shares, having a total worth of $8.27 million.